Ian Mortimer Receives the 2026 Bloom Burton Award
Xenon Pharmaceuticals Inc XENE
$37.25
▲ +1.44%
(+$0.53)
Open
$36.30
Prev Close
$36.72
Day Range
$36.20 – $37.43
52W Range
$36.07 – $72.66
Market Cap
$6.20B
Beta
0.09
EPS (TTM)
$-4.74
📋 Company Profile
| Industry | Biotechnology |
| Country | CA |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-10-17 |
| Shares Out. | 96,670,000 |
| Website | xenon-pharma.com/ ↗ |
| Phone | 16044843300 |
| Employees | 370 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$110.7M |
| Free Cash Flow | -$338.5M |
| Total Assets | $1.30B |
| Total Liabilities | $53.4M |
| Equity | $1.24B |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Xenon Pharmaceuticals Inc is a publicly traded company under the ticker symbol XENE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
26 analysts (2026-09-01)
📰 Latest News for XENE
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate
Xenon stock lost 30%, but the FDA story is more complicated
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Company News for Sep 21, 2026